scispace - formally typeset
E

Edmund G. Lowrie

Researcher at Tufts University

Publications -  47
Citations -  20698

Edmund G. Lowrie is an academic researcher from Tufts University. The author has contributed to research in topics: Hemodialysis & Dialysis. The author has an hindex of 30, co-authored 47 publications receiving 20351 citations.

Papers
More filters
Journal Article

K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification

TL;DR: In the early 1990s, the National Kidney Foundation (K/DOQI) developed a set of clinical practice guidelines to define chronic kidney disease and to classify stages in the progression of kidney disease.
Journal ArticleDOI

Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis

TL;DR: Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization, and the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperph phosphatemia.
Journal ArticleDOI

Death Risk in Hemodialysis Patients: The Predictive Value of Commonly Measured Variables and an Evaluation of Death Rate Differences Between Facilities

TL;DR: Strategies designed to improve the overall mortality statistic for dialysis patients in the United States would be better directed toward improving the quality of care for all patients, particularly high-risk patients, within their usual treatment settings rather than trying to identify facilities with high death rate for possible regulatory intervention.
Journal ArticleDOI

The Urea Reduction Ratio and Serum Albumin Concentration as Predictors of Mortality in Patients Undergoing Hemodialysis

TL;DR: Low urea reduction ratios during dialysis are associated with increased odds ratios for death, and these risks are worsened by inadequate nutrition.
Journal ArticleDOI

Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy

TL;DR: Patients who receive paricalcitol while undergoing long-term hemodialysis appear to have a significant survival advantage over those who receive calcitriol.